A significant challenge in vaccine development is the synthesis of a proper adjuvant. 1 An adjuvant, an indispensable part of a vaccine, enhances the magnitude, breadth, quality and longevity of specific immune responses, and reduces the amount of antigen needed for immunization. [2] [3] [4] [5] [6] [7] [8] [9] [10] However, as the most commonly used adjuvant in human vaccine, the aluminum compounds (alum) work only with certain diseases. 11 Alum provokes Th2 immune responses, although a Th1 immune response is required in anti-cancer immunity. 12 Therefore, the development of an adjuvant capable of stimulating robust Th1 anti-cancer immunity is crucial for cancer immunotherapy. Generally, a human adjuvant should be safe, stable, inexpensive, biodegradable, capable of antigen delivery, and act as an immunopotentiator. 13 (Fig. 1) . The rod-shaped FHA nanoparticles were synthesized using a simple hydrothermal method (Fig. 1A) . Typically, 3 mmol of Ca(NO 3 ) 2 , 0.5 g of hexadecyltrimethylammonium bromide (CTAB), 10 mL of ammonia solution (NH 3 ÁH 2 O), 6 mmol of trisodium citrate, 0.67 mmol of NaF, 2 mmol of (NH 4 ) 2 HPO 4 and 60 mL of ultrapure water were hydrothermally treated at 180 1C for 24 h. The product was collected, separated by centrifugation, and washed with ultrapure water and ethanol in sequence. Then, the obtained product was re-dispersed in 150 mL of 6 g L À1 NH 4 NO 3 in ethanol and stirred at 60 1C for 1 h to remove the template CTAB. The product was separated by centrifugation, washed with ultra-pure water several times, and freeze-dried to obtain the final FHA nanoparticles. HA nanoparticles were synthesized using the same method as FHA, without the addition of NaF. SEM and TEM images showed that the FHA nanoparticles were rod-shaped, with a uniform width of about 20 nm and a length of about 300 nm ( Fig observed in the FTIR spectra, indicating the complete removal of the template by the NH 4 NO 3 -ethanol solution (Fig. 2E ). The zeta potential of FHA nanoparticles was around À33.6 mV in PBS(À) (Fig. 2F ). The negative zeta potential below À30 mV implies that the FHA nanoparticles can be well dispersed and stable against aggregation in solution. HA nanoparticles showed a very similar XRD pattern and surface charge as compared with FHA, but the length of HA is only about 100 nm. 10 To evaluate the effect of particles on the cellular uptake of antigen, fluorescein conjugates of ovalbumin (F-OVA, a model antigen) loaded onto particles were cultured with bone marrow dentritic cells (BMDCs) for 4 h in vitro, respectively. Alum loaded with F-OVA and free F-OVA were used as controls. The amount of F-OVA internalized by the BMDCs was tested after washing twice with PBS(À). Interestingly, the amount of F-OVA internalized by BMDCs strongly depended on the adjuvant. BMDCs cultured with FHA-F-OVA and HA-F-OVA showed 17.2 and 13.2 times the F-OVA uptake compared to those with free F-OVA, respectively (Fig. 3B) . Moreover, BMDCs cultured with FHA-F-OVA showed significantly increased F-OVA uptake compared with those with HA-F-OVA. In contrast, BMDCs cultured with alum-F-OVA showed only 1.9 times the F-OVA uptake of those with free F-OVA. The cellular uptake of F-OVA by BMDCs was further confirmed by confocal microscopy images. Free F-OVA was slightly engulfed by BMDCs after 4 h (Fig. 3C1-C4 ). In contrast, FHA nanoparticles loaded with F-OVA were efficiently engulfed by BMDCs after 4 h (Fig. 3D1-D4 ).
The effect of FHA nanoparticles on antigen-presenting cell accumulation and cross-presentation of SIINFEKL-MHCI with antigen-presenting cells was studied. Cells around the immunization site were harvested and tested by flow cytometry, 14 days after the first immunization (Fig. 4A) . (Fig. 4B and Fig. S5, ESI †) .
The rod-shaped morphology of FHA nanoparticles is favorable for the efficient antigen cellular uptake. The particle size and shape are very important parameters to control the nonspecific cellular uptake and subsequent cellular responses. Mesoporous silica particles with a long-rod-shaped morphology were taken up in larger amounts and faster internalization rates than those with a short-rod-shaped or round-shaped morphology. 24 Subsequently, the efficient cellular uptake of FHA nanoparticles will be beneficial for the delivery of the adsorbed antigen to The uptake of antigens by the immune cell is the first step that eventually leads to a specific immune response. 25, 26 Maximizing the efficiency of antigen presentation is considered to be the key point for the successful development of a therapeutic immune response.
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In vitro immunogenic activity and cytotoxicity of rod-shaped HA and FHA nanoparticles were evaluated by culturing the nanoparticles with BMDCs (Fig. 5A ). BMDCs cultured with FHA showed the highest interferon-g (IFN-g) and interleukin-1b (IL-1b) secretion among all the samples. At 50 mg mL À1 of particle concentration, BMDCs cultured with FHA showed significantly enhanced IFN-g and IL-1b secretion compared to those cultured with alum and medium ( Fig. 5B and C) . Rod-shaped FHA showed no cytotoxicity at 20-50 mg mL À1 as tested by BMDCs (Fig. 5D) . Moreover, rod-shaped FHA nanoparticles showed no obvious cytotoxicity at 5-50 mg mL À1 as tested by cell viability and lactate dehydrogenase (LDH) cytotoxicity of NIH3T3 cells (Fig. S1 and S2, ESI †). Anti-cancer immunity of the rod-shaped FHA nanoparticles was tested using mouse lymphoma E.G7-OVA cells (Fig. 6A ). Mice immunized with alum-OVA and without immunization showed obvious tumor growth 4w after E.G7-OVA challenge (Fig. 6B, red circle) . In contrast, FHA-OVA immunized mice showed significantly smaller tumor size than those immunized with alum-OVA or without immunization (Fig. 6B) . Percentage of mice without cancer or with cancer smaller than 15 mm for FHA-OVA, Alum-OVA and saline injected mice 4w after E. G7-OVA challenge was 60%, 20% and 0%, respectively (Fig. 6C) . The cancer volume of FHA-OVA, Alum-OVA and saline injected mice 4w after E.G7-OVA challenge was 1573 AE 969, 4221 AE 2845 and 7013 AE 2866 mm 3 , respectively (Fig. 6D) . Similarly, mice immunized by an established Th1-biased control adjuvant (poly IC) 28, 29 markedly inhibited cancer challenge (Fig. 6E ). In addition, the anti-cancer effect was not due to nonspecific cytotoxicity of FHA, as FHA without antigen OVA did not show any anti-cancer response (Fig. 6F ).
To further clarify the mechanism of the anti-cancer immunity of the rod-shaped FHA nanoparticles, the immune related cytokine secretion from the lymphocytes was studied (Fig. 7A) . The rod-shaped FHA nanoparticles significantly improved OVAspecific IFN-g secretion by lymphocytes than alum adjuvant and without adjuvant groups ex vivo. Mice treated with the rod-shaped FHA nanoparticles showed maximum IFN-g secretion at 969 AE 567 pg mL , when stimulated by 100 mg mL À1 OVA ex vivo (Fig. 7B) . IFN-g is a cytokine critical for innate and adaptive immunity, which has immunoregulatory and anti-cancer properties, and can direct cytotoxic effects on cancer cells in conjunction with the cancer necrosis factor. 30 Moreover, IFN-g is a key cytokine Besides, safety is another key requirement for a successful adjuvant. Since rod-shaped FHA nanoparticles showed no obvious cytotoxicity, the FHA nanoparticles are a good candidate for an adjuvant.
To conclude, FHA nanoparticles with rod-shaped morphology were synthesized using a simple hydrothermal method. For the first time, we showed that the rod-shaped FHA nanoparticles significantly improve the cellular uptake of a model antigen in vitro, improved antigen presentation in vivo, and improved immune related cytokine secretion in vitro and ex vivo. 
Notes and references

